No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, d3ohuF_, 1.0000, 0.00, 1.000, 118, 118, CRYSTAL STRUCTURE OF THE HUMAN BACH2 POZ DOMAIN FORM I
2, d3ohvE_, 0.9954, 0.27, 1.000, 119, 118, CRYSTAL STRUCTURE OF THE HUMAN BACH2 POZ DOMAIN FORM II
3, d3ohuD_, 0.9786, 0.64, 1.000, 120, 118, CRYSTAL STRUCTURE OF THE HUMAN BACH2 POZ DOMAIN FORM I
4, d3ohvA1, 0.9782, 0.68, 1.000, 121, 118, CRYSTAL STRUCTURE OF THE HUMAN BACH2 POZ DOMAIN FORM II
5, d3ohuA1, 0.9775, 0.70, 1.000, 121, 118, CRYSTAL STRUCTURE OF THE HUMAN BACH2 POZ DOMAIN FORM I
6, d3ohvC_, 0.9722, 0.76, 1.000, 119, 118, CRYSTAL STRUCTURE OF THE HUMAN BACH2 POZ DOMAIN FORM II
7, d3ohvF_, 0.9516, 0.85, 0.974, 119, 116, CRYSTAL STRUCTURE OF THE HUMAN BACH2 POZ DOMAIN FORM II
8, d3ohuE_, 0.9481, 0.72, 1.000, 117, 115, CRYSTAL STRUCTURE OF THE HUMAN BACH2 POZ DOMAIN FORM I
9, d3ohvD_, 0.9469, 0.59, 0.982, 117, 114, CRYSTAL STRUCTURE OF THE HUMAN BACH2 POZ DOMAIN FORM II
10, d2z8hA1, 0.9328, 1.27, 0.650, 135, 117, STRUCTURE OF MOUSE BACH1 BTB DOMAIN
11, d3ohuC_, 0.9236, 1.27, 0.650, 135, 117, CRYSTAL STRUCTURE OF THE HUMAN BACH2 POZ DOMAIN FORM I
12, d2ihcA_, 0.9127, 0.57, 1.000, 113, 111, CRYSTAL STRUCTURE OF THE BRIC-A-BRAC (BTB) DOMAIN OF HUMAN BACH1
13, d3ohuB_, 0.9026, 1.15, 0.664, 117, 113, CRYSTAL STRUCTURE OF THE HUMAN BACH2 POZ DOMAIN FORM I
14, d2ihcC1, 0.8993, 1.68, 0.965, 120, 115, CRYSTAL STRUCTURE OF THE BRIC-A-BRAC (BTB) DOMAIN OF HUMAN BACH1
15, d3ohvB_, 0.8975, 1.44, 0.661, 116, 112, CRYSTAL STRUCTURE OF THE HUMAN BACH2 POZ DOMAIN FORM II
16, d2ihcB1, 0.8970, 1.59, 1.000, 121, 114, CRYSTAL STRUCTURE OF THE BRIC-A-BRAC (BTB) DOMAIN OF HUMAN BACH1
17, d2ihcD_, 0.8924, 0.78, 0.661, 111, 109, CRYSTAL STRUCTURE OF THE BRIC-A-BRAC (BTB) DOMAIN OF HUMAN BACH1
18, d3bimD_, 0.8880, 1.12, 0.664, 115, 110, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN DIMER IN COMPLEX WITH THE BCOR BBD COREPRESSOR PEPTIDE
19, d4cxiA_, 0.8849, 1.87, 0.374, 124, 115, BTB DOMAIN OF KEAP1
20, d5mw6A_, 0.8848, 1.72, 0.259, 130, 116, CRYSTAL STRUCTURE OF THE BCL6 BTB-DOMAIN WITH COMPOUND 1
21, d5gitA_, 0.8848, 1.73, 0.383, 122, 115, BTB DOMAIN OF KEAP1 IN COMPLEX WITH XX3
22, d1r28A_, 0.8846, 1.71, 0.259, 130, 116, CRYSTAL STRUCTURE OF THE B-CELL LYMPHOMA 6 (BCL6) BTB DOMAIN TO 2.2 ANGSTROM
23, d1r2bA_, 0.8845, 1.92, 0.379, 122, 116, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN COMPLEXED WITH A SMRT CO-REPRESSOR PEPTIDE
24, d3bimA_, 0.8844, 1.77, 0.374, 125, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN DIMER IN COMPLEX WITH THE BCOR BBD COREPRESSOR PEPTIDE
25, d3bimG_, 0.8842, 1.77, 0.374, 125, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN DIMER IN COMPLEX WITH THE BCOR BBD COREPRESSOR PEPTIDE
26, d3bimH_, 0.8839, 1.94, 0.374, 125, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN DIMER IN COMPLEX WITH THE BCOR BBD COREPRESSOR PEPTIDE
27, d4cxjA_, 0.8826, 1.89, 0.374, 122, 115, BTB DOMAIN OF KEAP1 C151W MUTANT
28, d3bimB_, 0.8822, 1.90, 0.374, 122, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN DIMER IN COMPLEX WITH THE BCOR BBD COREPRESSOR PEPTIDE
29, d3bimC_, 0.8820, 1.75, 0.267, 131, 116, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN DIMER IN COMPLEX WITH THE BCOR BBD COREPRESSOR PEPTIDE
30, d1r2bB_, 0.8818, 1.94, 0.374, 124, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN COMPLEXED WITH A SMRT CO-REPRESSOR PEPTIDE
31, d4u2mB2, 0.8812, 1.91, 0.374, 125, 115, CRYSTAL STRUCTURE OF A COMPLEX OF THE MIZ1- AND BCL6 POZ DOMAINS.
32, d3bimE_, 0.8812, 1.78, 0.374, 123, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN DIMER IN COMPLEX WITH THE BCOR BBD COREPRESSOR PEPTIDE
33, d4u2mD2, 0.8789, 1.89, 0.374, 123, 115, CRYSTAL STRUCTURE OF A COMPLEX OF THE MIZ1- AND BCL6 POZ DOMAINS.
34, d4cxtA_, 0.8786, 1.90, 0.374, 123, 115, BTB DOMAIN OF KEAP1 IN COMPLEX WITH CDDO
35, d5n1xC_, 0.8780, 2.01, 0.379, 123, 116, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH PYRAZOLO- PYRIMIDINE LIGAND
36, d1r28B_, 0.8775, 1.77, 0.259, 132, 116, CRYSTAL STRUCTURE OF THE B-CELL LYMPHOMA 6 (BCL6) BTB DOMAIN TO 2.2 ANGSTROM
37, d3bimF_, 0.8773, 1.77, 0.259, 132, 116, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN DIMER IN COMPLEX WITH THE BCOR BBD COREPRESSOR PEPTIDE
38, d5n20A_, 0.8758, 1.94, 0.371, 121, 116, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH PYRAZOLO- PYRIMIDINE LIGAND
39, d4u2mA2, 0.8753, 1.94, 0.379, 122, 116, CRYSTAL STRUCTURE OF A COMPLEX OF THE MIZ1- AND BCL6 POZ DOMAINS.
40, d5n1zA_, 0.8751, 1.74, 0.377, 122, 114, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH PYRAZOLO- PYRIMIDINE MACROCYCLIC LIGAND
41, d3lbzA_, 0.8751, 1.79, 0.374, 123, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN COMPLEXED WITH THE SMALL MOLECULE INHIBITOR 79-6
42, d4u2mC2, 0.8747, 1.96, 0.374, 123, 115, CRYSTAL STRUCTURE OF A COMPLEX OF THE MIZ1- AND BCL6 POZ DOMAINS.
43, d5n21B_, 0.8746, 1.79, 0.374, 123, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH PYRAZOLO- PYRIMIDINE LIGAND
44, d5mwdA_, 0.8743, 1.76, 0.383, 122, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB-DOMAIN WITH COMPOUND 2
45, d5n21A_, 0.8726, 1.96, 0.374, 123, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH PYRAZOLO- PYRIMIDINE LIGAND
46, d5x4nA1, 0.8721, 1.79, 0.383, 122, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH COMPOUND 4
47, d1r29A_, 0.8720, 1.76, 0.374, 122, 115, CRYSTAL STRUCTURE OF THE B-CELL LYMPHOMA 6 (BCL6) BTB DOMAIN TO 1.3 ANGSTROM
48, d3lbzB_, 0.8716, 1.81, 0.383, 122, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN COMPLEXED WITH THE SMALL MOLECULE INHIBITOR 79-6
49, d5x4qA1, 0.8714, 1.90, 0.374, 125, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH COMPOUND 7
50, d5x4pA1, 0.8711, 1.81, 0.374, 122, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH COMPOUND 6
51, d5mw2A_, 0.8710, 1.79, 0.383, 122, 115, CRYSTAL STRUCTURE OF BCL-6 BTB-DOMAIN WITH BI-3802
52, d5x4oA1, 0.8703, 1.81, 0.374, 125, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH COMPOUND 5
53, d5x9pA1, 0.8701, 2.03, 0.371, 125, 116, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH COMPOUND 5
54, d5x4mA1, 0.8697, 1.81, 0.374, 122, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH COMPOUND 1
55, d5n1xB_, 0.8695, 1.92, 0.374, 125, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH PYRAZOLO- PYRIMIDINE LIGAND
56, d5x9oA1, 0.8682, 1.83, 0.374, 125, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH COMPOUND 1A
57, d4cp3A1, 0.8669, 2.04, 0.371, 125, 116, THE STRUCTURE OF BCL6 BTB (POZ) DOMAIN IN COMPLEX WITH THE ANSAMYCIN ANTIBIOTIC RIFABUTIN.
58, d5mw6B_, 0.8661, 1.95, 0.371, 121, 116, CRYSTAL STRUCTURE OF THE BCL6 BTB-DOMAIN WITH COMPOUND 1
59, d2nn2A_, 0.8653, 1.85, 0.374, 125, 115, CRYSTAL STRUCTURE OF THE BTB DOMAIN FROM THE LRF/ZBTB7 TRANSCRIPTIONAL REGULATOR
60, d2if5A_, 0.8621, 1.85, 0.386, 119, 114, STRUCTURE OF THE POZ DOMAIN OF HUMAN LRF A MASTER REGULATOR OF ONCOGENESIS
61, d2nn2B_, 0.8619, 1.94, 0.386, 119, 114, CRYSTAL STRUCTURE OF THE BTB DOMAIN FROM THE LRF/ZBTB7 TRANSCRIPTIONAL REGULATOR
62, d5n1xA1, 0.8586, 1.80, 0.363, 117, 113, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH PYRAZOLO- PYRIMIDINE LIGAND
63, d3e4uB_, 0.8568, 1.80, 0.363, 117, 113, CRYSTAL STRUCTURE OF THE WILD-TYPE HUMAN BCL6 BTB/POZ DOMAIN
64, d5n1xD1, 0.8566, 1.95, 0.360, 115, 114, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH PYRAZOLO- PYRIMIDINE LIGAND
65, d4cp3B1, 0.8554, 1.82, 0.363, 117, 113, THE STRUCTURE OF BCL6 BTB (POZ) DOMAIN IN COMPLEX WITH THE ANSAMYCIN ANTIBIOTIC RIFABUTIN.
66, d3ga1B_, 0.8535, 1.99, 0.377, 120, 114, CRYSTAL STRUCTURE OF THE HUMAN NAC1 POZ DOMAIN
67, d5dafA_, 0.8530, 1.88, 0.375, 120, 112, CRYSTAL STRUCTURE OF HUMAN KEAP1 BTB DOMAIN IN COMPLEX WITH SMALL MOLECULE TX64063
68, d1buoA_, 0.8505, 2.03, 0.386, 117, 114, BTB DOMAIN FROM PLZF
69, d3e4uD_, 0.8495, 1.93, 0.381, 120, 113, CRYSTAL STRUCTURE OF THE WILD-TYPE HUMAN BCL6 BTB/POZ DOMAIN
70, d5dadA_, 0.8477, 1.75, 0.345, 122, 113, CRYSTAL STRUCTURE OF HUMAN KEAP1 BTB DOMAIN IN COMPLEX WITH SMALL MOLECULE TX64014
71, d1cs3A_, 0.8472, 1.75, 0.345, 122, 113, STRUCTURE OF BTB/POZ TRANSCRIPTION REPRESSION DOMAIN FROM PROMELOCYTIC LEUKEMIA ZINC FINGER ONCOPROTEIN
72, d3fkcA_, 0.8461, 1.67, 0.279, 121, 111, CRYSTAL STRUCTURE OF HUMAN ZINC FINGER AND BTB DOMAIN CONTAINING 33
73, d3m4tA_, 0.8445, 1.92, 0.307, 121, 114, CRYSTAL STRUCTURE OF THE BTB DOMAIN FROM KAISO/ZBTB33 FORM I
74, d3e4uA_, 0.8444, 1.92, 0.307, 121, 114, CRYSTAL STRUCTURE OF THE WILD-TYPE HUMAN BCL6 BTB/POZ DOMAIN
75, d3e4uC_, 0.8381, 1.89, 0.375, 118, 112, CRYSTAL STRUCTURE OF THE WILD-TYPE HUMAN BCL6 BTB/POZ DOMAIN
76, d3m8vA_, 0.8370, 1.72, 0.279, 123, 111, CRYSTAL STRUCTURE OF THE BTB DOMAIN FROM KAISO/ZBTB33 FORM II
77, d3ga1A_, 0.8360, 1.99, 0.316, 116, 114, CRYSTAL STRUCTURE OF THE HUMAN NAC1 POZ DOMAIN
78, d3e4uE_, 0.8346, 1.51, 0.303, 113, 109, CRYSTAL STRUCTURE OF THE WILD-TYPE HUMAN BCL6 BTB/POZ DOMAIN
79, d2vpkA1, 0.8273, 1.59, 0.300, 115, 110, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN MYONEURIN
80, d4u2nB2, 0.8250, 1.59, 0.300, 115, 110, CRYSTAL STRUCTURE OF A COMPLEX OF THE MIZ1- AND NAC1 POZ DOMAINS.
81, d4u2nA2, 0.8193, 1.92, 0.375, 119, 112, CRYSTAL STRUCTURE OF A COMPLEX OF THE MIZ1- AND NAC1 POZ DOMAINS.
82, d2ppiA1, 0.8131, 2.05, 0.381, 119, 113, STRUCTURE OF THE BTB (TRAMTRACK AND BRIC A BRAC) DOMAIN OF HUMAN GIGAXONIN
83, d3e4uF_, 0.8112, 1.67, 0.300, 114, 110, CRYSTAL STRUCTURE OF THE WILD-TYPE HUMAN BCL6 BTB/POZ DOMAIN
84, p5h7hA_, 0.8020, 1.96, 0.333, 113, 111, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH F1324(10-13)
85, p4hxiA1, 0.7907, 1.86, 0.376, 112, 109, CRYSTAL STRUCTURE OF KLHL3/CUL3 COMPLEX
86, p5h7gB_, 0.7810, 2.03, 0.360, 113, 111, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH F1324
87, d2yy9B1, 0.7809, 2.03, 0.360, 113, 111, CRYSTAL STRUCTURE OF BTB DOMAIN FROM MOUSE HKR3
88, d3b84A1, 0.7806, 1.81, 0.336, 119, 110, CRYSTAL STRUCTURE OF THE HUMAN BTB DOMAIN OF THE KRUEPPEL RELATED ZINC FINGER PROTEIN 3 (HKR3)
89, d4u2mB1, 0.7798, 1.66, 0.343, 117, 108, CRYSTAL STRUCTURE OF A COMPLEX OF THE MIZ1- AND BCL6 POZ DOMAINS.
90, p5h7gA_, 0.7781, 2.30, 0.221, 113, 113, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH F1324
91, d4u2mD1, 0.7705, 2.30, 0.221, 113, 113, CRYSTAL STRUCTURE OF A COMPLEX OF THE MIZ1- AND BCL6 POZ DOMAINS.
92, p5nlbA_, 0.7630, 1.89, 0.393, 110, 107, CRYSTAL STRUCTURE OF HUMAN CUL3 N-TERMINAL DOMAIN BOUND TO KEAP1 BTB AND 3-BOX
93, d2yy9A1, 0.7624, 1.95, 0.387, 114, 106, CRYSTAL STRUCTURE OF BTB DOMAIN FROM MOUSE HKR3
94, d4u2mC1, 0.7588, 1.95, 0.292, 111, 106, CRYSTAL STRUCTURE OF A COMPLEX OF THE MIZ1- AND BCL6 POZ DOMAINS.
95, d3m52A1, 0.7561, 1.95, 0.292, 111, 106, CRYSTAL STRUCTURE OF THE BTB DOMAIN FROM THE MIZ-1/ZBTB17 TRANSCRIPTION REGULATOR
96, d2q81A1, 0.7519, 1.79, 0.402, 110, 102, CRYSTAL STRUCTURE OF THE MIZ-1 BTB/POZ DOMAIN
97, d2q81B1, 0.7467, 2.16, 0.377, 107, 106, CRYSTAL STRUCTURE OF THE MIZ-1 BTB/POZ DOMAIN
98, d2q81D_, 0.7457, 2.26, 0.355, 112, 110, CRYSTAL STRUCTURE OF THE MIZ-1 BTB/POZ DOMAIN
99, d3m52B1, 0.7379, 2.26, 0.355, 112, 110, CRYSTAL STRUCTURE OF THE BTB DOMAIN FROM THE MIZ-1/ZBTB17 TRANSCRIPTION REGULATOR
100, d2q81C1, 0.7358, 1.89, 0.415, 106, 106, CRYSTAL STRUCTURE OF THE MIZ-1 BTB/POZ DOMAIN
101, p4eozC_, 0.7325, 1.96, 0.408, 110, 103, CRYSTAL STRUCTURE OF THE SPOP BTB DOMAIN COMPLEXED WITH THE CUL3 N- TERMINAL DOMAIN
102, p4apfA2, 0.7294, 2.24, 0.449, 108, 107, CRYSTAL STRUCTURE OF THE HUMAN KLHL11-CUL3 COMPLEX AT 3.1A RESOLUTION
103, p4eozA_, 0.7290, 1.54, 0.293, 108, 99, CRYSTAL STRUCTURE OF THE SPOP BTB DOMAIN COMPLEXED WITH THE CUL3 N- TERMINAL DOMAIN
104, p3hu6B2, 0.7279, 1.85, 0.392, 105, 102, STRUCTURES OF SPOP-SUBSTRATE COMPLEXES: INSIGHTS INTO MOLECULAR ARCHITECTURES OF BTB-CUL3 UBIQUITIN LIGASES: SPOPMATHX/BTB/3-BOX-PUCSBC1
105, p4j8zA1, 0.7242, 1.74, 0.436, 101, 101, CRYSTAL STRUCTURE OF THE HUMAN SPOP BTB DOMAIN
106, p4ap2A2, 0.7241, 2.51, 0.430, 115, 107, CRYSTAL STRUCTURE OF THE HUMAN KLHL11-CUL3 COMPLEX AT 2.8A RESOLUTION
107, d4u2nB1, 0.7234, 2.51, 0.430, 115, 107, CRYSTAL STRUCTURE OF A COMPLEX OF THE MIZ1- AND NAC1 POZ DOMAINS.
108, p4j8zB1, 0.7213, 2.73, 0.431, 113, 109, CRYSTAL STRUCTURE OF THE HUMAN SPOP BTB DOMAIN
109, d4u2mA1, 0.7199, 2.50, 0.422, 114, 109, CRYSTAL STRUCTURE OF A COMPLEX OF THE MIZ1- AND BCL6 POZ DOMAINS.
110, p3hqiA2, 0.7175, 2.57, 0.441, 114, 111, STRUCTURES OF SPOP-SUBSTRATE COMPLEXES: INSIGHTS INTO MOLECULAR ARCHITECTURES OF BTB-CUL3 UBIQUITIN LIGASES: SPOPMATHX/BTB/3-BOX-PUCSBC1
111, d4u2nA1, 0.7163, 2.57, 0.421, 115, 107, CRYSTAL STRUCTURE OF A COMPLEX OF THE MIZ1- AND NAC1 POZ DOMAINS.
112, p3hqiB2, 0.7132, 2.75, 0.435, 113, 108, STRUCTURES OF SPOP-SUBSTRATE COMPLEXES: INSIGHTS INTO MOLECULAR ARCHITECTURES OF BTB-CUL3 UBIQUITIN LIGASES: SPOPMATHX/BTB/3-BOX-PUCSBC1
113, d3m5bA_, 0.7103, 2.46, 0.226, 116, 106, CRYSTAL STRUCTURE OF THE BTB DOMAIN FROM FAZF/ZBTB32
114, d3m5bB_, 0.7095, 2.04, 0.300, 109, 100, CRYSTAL STRUCTURE OF THE BTB DOMAIN FROM FAZF/ZBTB32
115, p3i3nB2, 0.7047, 2.04, 0.300, 109, 100, CRYSTAL STRUCTURE OF THE BTB-BACK DOMAINS OF HUMAN KLHL11
116, p5eupA_, 0.7036, 2.54, 0.236, 114, 106, STRUCTURE OF THE DROSOPHILA MELANOGASTER CP190 BTB DOMAIN
117, p4u77A_, 0.6939, 2.36, 0.229, 142, 105, BTB DOMAIN FROM DROSOPHILA CP190
118, p3i3nA2, 0.6879, 2.36, 0.229, 142, 105, CRYSTAL STRUCTURE OF THE BTB-BACK DOMAINS OF HUMAN KLHL11
119, p4uyiA_, 0.6569, 2.37, 0.233, 112, 103, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN SLX4 (BTBD12)
120, p3hveA2, 0.6452, 2.03, 0.303, 108, 99, STRUCTURES OF SPOP-SUBSTRATE COMPLEXES: INSIGHTS INTO MOLECULAR ARCHITECTURES OF BTB-CUL3 UBIQUITIN LIGASES: GIGAXONINBTB/3-BOX
121, p6gfcB_, 0.6405, 2.35, 0.462, 104, 104, STRUCTURE OF THE BTB/POZ DOMAIN OF HUMAN 90K 
122, p2vkpB_, 0.6388, 2.54, 0.231, 112, 104, CRYSTAL STRUCTURE OF BTB DOMAIN FROM BTBD6
123, p6gfcG_, 0.6378, 1.88, 0.443, 97, 97, STRUCTURE OF THE BTB/POZ DOMAIN OF HUMAN 90K 
124, p6gfbB_, 0.6363, 2.19, 0.235, 139, 102, STRUCTURE OF THE BTB/POZ DOMAIN OF HUMAN 90K 
125, p6gfcD_, 0.6353, 2.27, 0.456, 103, 103, STRUCTURE OF THE BTB/POZ DOMAIN OF HUMAN 90K 
126, p4zouA_, 0.6348, 2.27, 0.238, 102, 101, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF SLX4
127, p2vkpA_, 0.6348, 2.16, 0.263, 109, 99, CRYSTAL STRUCTURE OF BTB DOMAIN FROM BTBD6
128, p6gfbA_, 0.6298, 2.16, 0.263, 109, 99, STRUCTURE OF THE BTB/POZ DOMAIN OF HUMAN 90K 
129, p6gfcC_, 0.6296, 2.17, 0.263, 109, 99, STRUCTURE OF THE BTB/POZ DOMAIN OF HUMAN 90K 
130, p6gfcA_, 0.6288, 2.36, 0.303, 107, 99, STRUCTURE OF THE BTB/POZ DOMAIN OF HUMAN 90K 
131, p6byhB_, 0.6171, 2.04, 0.286, 105, 98, UBIQUITIN VARIANT (UBV.FL11.1) BOUND TO A HUMAN SKP1-FBL11 FRAGMENT COMPLEX. 
132, p5an3D_, 0.6155, 2.29, 0.283, 106, 99, STRUCTURE OF AN SGT1-SKP1 COMPLEX
133, p2astA_, 0.6141, 2.29, 0.283, 106, 99, CRYSTAL STRUCTURE OF SKP1-SKP2-CKS1 IN COMPLEX WITH A P27 PEPTIDE
134, p6c16B_, 0.6120, 1.94, 0.312, 98, 93, UBIQUITIN VARIANT (UBV.FBL10.1) BOUND TO A HUMAN SKP1-FBL11 FRAGMENT COMPLEX. 
135, p6byhA_, 0.6120, 3.09, 0.189, 114, 106, UBIQUITIN VARIANT (UBV.FL11.1) BOUND TO A HUMAN SKP1-FBL11 FRAGMENT COMPLEX. 
136, p6byhG_, 0.6088, 3.09, 0.189, 114, 106, UBIQUITIN VARIANT (UBV.FL11.1) BOUND TO A HUMAN SKP1-FBL11 FRAGMENT COMPLEX. 
137, p5vztA_, 0.6065, 1.63, 0.233, 86, 86, CRYSTAL STRUCTURE OF THE SKP1-FBXO31 COMPLEX
138, d5bxhA1, 0.6052, 2.80, 0.130, 116, 100, CRYSTAL STRUCTURE OF PENTAMERIC KCTD9 BTB DOMAIN
139, d5bxhE_, 0.6050, 2.58, 0.213, 105, 94, CRYSTAL STRUCTURE OF PENTAMERIC KCTD9 BTB DOMAIN
140, p3hveB2, 0.6050, 2.58, 0.213, 105, 94, STRUCTURES OF SPOP-SUBSTRATE COMPLEXES: INSIGHTS INTO MOLECULAR ARCHITECTURES OF BTB-CUL3 UBIQUITIN LIGASES: GIGAXONINBTB/3-BOX
141, d5bxhC1, 0.6049, 2.82, 0.130, 113, 100, CRYSTAL STRUCTURE OF PENTAMERIC KCTD9 BTB DOMAIN
142, p6bvaC_, 0.6047, 2.93, 0.170, 112, 100, UBIQUITIN VARIANT (UBV.FL10.1) BOUND TO A HUMAN SKP1-FBL10 FRAGMENT COMPLEX. 
143, p6bvaD_, 0.6043, 2.81, 0.130, 112, 100, UBIQUITIN VARIANT (UBV.FL10.1) BOUND TO A HUMAN SKP1-FBL10 FRAGMENT COMPLEX. 
144, p5vztC_, 0.6043, 2.77, 0.202, 107, 99, CRYSTAL STRUCTURE OF THE SKP1-FBXO31 COMPLEX
145, p5vzuA_, 0.6037, 2.44, 0.209, 99, 91, CRYSTAL STRUCTURE OF THE SKP1-FBXO31-CYCLIN D1 COMPLEX
146, d5a6rC_, 0.6034, 2.91, 0.160, 108, 100, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD17
147, p5vzuC_, 0.6028, 2.84, 0.131, 108, 99, CRYSTAL STRUCTURE OF THE SKP1-FBXO31-CYCLIN D1 COMPLEX
148, d3drzA_, 0.6028, 2.93, 0.150, 108, 100, X-RAY CRYSTAL STRUCTURE OF THE N-TERMINAL BTB DOMAIN OF HUMAN KCTD5 PROTEIN
149, d5a6rA_, 0.6027, 2.33, 0.156, 113, 90, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD17
150, d5a6rD_, 0.6026, 2.14, 0.195, 103, 87, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD17
151, d5a6rE_, 0.6019, 2.34, 0.182, 107, 88, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD17
152, d5a6rB_, 0.6017, 2.40, 0.189, 111, 90, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD17
153, p5xylA_, 0.6011, 2.36, 0.146, 115, 89, SOLUTION STRUCTURE OF SKP1 FROM HOMO SAPIENS 
154, p5v4bA_, 0.6007, 2.29, 0.193, 107, 88, CRYSTAL STRUCTURE OF THE SKP1-FBXW7-DISC1 COMPLEX
155, d4uijA_, 0.6000, 2.32, 0.184, 107, 87, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF KCTD13
156, d5ftaA_, 0.5995, 2.58, 0.172, 99, 87, CRYSTAL STRUCTURE OF THE N-TERMINAL BTB DOMAIN OF HUMAN KCTD10
157, d4uijC_, 0.5991, 2.41, 0.174, 97, 86, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF KCTD13
158, d4uesA_, 0.5991, 1.53, 0.250, 80, 80,  
159, d5bxhB1, 0.5989, 2.45, 0.174, 97, 86, CRYSTAL STRUCTURE OF PENTAMERIC KCTD9 BTB DOMAIN
160, d4uijD_, 0.5989, 2.36, 0.191, 116, 89, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF KCTD13
161, d4uesC_, 0.5985, 2.37, 0.191, 116, 89,  
162, d5ftaC_, 0.5982, 2.34, 0.184, 105, 87, CRYSTAL STRUCTURE OF THE N-TERMINAL BTB DOMAIN OF HUMAN KCTD10
163, d5bxdA_, 0.5972, 2.33, 0.184, 107, 87, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 2
164, d5bxhD1, 0.5971, 2.59, 0.227, 102, 88, CRYSTAL STRUCTURE OF PENTAMERIC KCTD9 BTB DOMAIN
165, p3v7dA_, 0.5966, 2.34, 0.184, 105, 87, CRYSTAL STRUCTURE OF SCSKP1-SCCDC4-PSIC1 PEPTIDE COMPLEX
166, p3v7dC_, 0.5956, 2.74, 0.191, 103, 89, CRYSTAL STRUCTURE OF SCSKP1-SCCDC4-PSIC1 PEPTIDE COMPLEX
167, p3drxC1, 0.5956, 2.61, 0.227, 102, 88, X-RAY CRYSTAL STRUCTURE OF HUMAN KCTD5 PROTEIN CRYSTALLIZED IN HIGH- SALT BUFFER
168, p3oglM_, 0.5955, 2.48, 0.230, 101, 87, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH JA-ISOLEUCINE AND THE JAZ1 DEGRON
169, d3drzB_, 0.5954, 2.64, 0.227, 101, 88, X-RAY CRYSTAL STRUCTURE OF THE N-TERMINAL BTB DOMAIN OF HUMAN KCTD5 PROTEIN
170, p6f07D_, 0.5951, 2.47, 0.230, 101, 87, CBF3 CORE COMPLEX
171, p3dryA1, 0.5948, 2.49, 0.154, 106, 91, X-RAY CRYSTAL STRUCTURE OF HUMAN KCTD5 PROTEIN CRYSTALLIZED IN LOW- SALT BUFFER
172, d4uijB_, 0.5946, 2.37, 0.184, 110, 87, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF KCTD13
173, p3ogmM_, 0.5946, 2.37, 0.184, 110, 87, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND THE JAZ1 DEGRON
174, p3oglO_, 0.5945, 2.64, 0.159, 104, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH JA-ISOLEUCINE AND THE JAZ1 DEGRON
175, p3dryB1, 0.5945, 2.64, 0.159, 104, 88, X-RAY CRYSTAL STRUCTURE OF HUMAN KCTD5 PROTEIN CRYSTALLIZED IN LOW- SALT BUFFER
176, p3dryE1, 0.5943, 2.67, 0.170, 101, 88, X-RAY CRYSTAL STRUCTURE OF HUMAN KCTD5 PROTEIN CRYSTALLIZED IN LOW- SALT BUFFER
177, p3dryC1, 0.5943, 2.57, 0.161, 102, 87, X-RAY CRYSTAL STRUCTURE OF HUMAN KCTD5 PROTEIN CRYSTALLIZED IN LOW- SALT BUFFER
178, d5a15B_, 0.5939, 2.66, 0.159, 102, 88, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
179, p3ogkM_, 0.5939, 2.44, 0.176, 97, 85, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND AN INCOMPLETE JAZ1 DEGRON
180, p3ogkC_, 0.5939, 2.59, 0.161, 101, 87, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND AN INCOMPLETE JAZ1 DEGRON
181, p6gfcF_, 0.5938, 2.68, 0.149, 97, 87, STRUCTURE OF THE BTB/POZ DOMAIN OF HUMAN 90K 
182, p3ogmC_, 0.5938, 2.68, 0.161, 97, 87, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND THE JAZ1 DEGRON
183, p3oglK_, 0.5938, 2.71, 0.124, 101, 89, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH JA-ISOLEUCINE AND THE JAZ1 DEGRON
184, p3oglC_, 0.5938, 2.73, 0.172, 99, 87, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH JA-ISOLEUCINE AND THE JAZ1 DEGRON
185, d5bxbG1, 0.5936, 2.26, 0.186, 107, 86, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 1
186, p3ogmK_, 0.5936, 2.22, 0.198, 107, 86, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND THE JAZ1 DEGRON
187, d5a15G_, 0.5935, 3.28, 0.204, 111, 93, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
188, d5bxbF1, 0.5934, 2.48, 0.195, 105, 87, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 1
189, d5bxbA1, 0.5934, 2.81, 0.191, 103, 89, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 1
190, p3ogkO_, 0.5932, 2.28, 0.186, 116, 86, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND AN INCOMPLETE JAZ1 DEGRON
191, p3ogkK_, 0.5932, 2.28, 0.186, 116, 86, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND AN INCOMPLETE JAZ1 DEGRON
192, p3ogmG_, 0.5930, 2.83, 0.191, 108, 89, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND THE JAZ1 DEGRON
193, p3oglG_, 0.5928, 2.63, 0.161, 103, 87, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH JA-ISOLEUCINE AND THE JAZ1 DEGRON
194, p3oglI_, 0.5927, 2.82, 0.202, 105, 89, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH JA-ISOLEUCINE AND THE JAZ1 DEGRON
195, d5a15J_, 0.5926, 2.69, 0.193, 105, 88, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
196, p3oglE_, 0.5925, 2.81, 0.191, 104, 89, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH JA-ISOLEUCINE AND THE JAZ1 DEGRON
197, p3oglA_, 0.5925, 2.85, 0.191, 104, 89, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH JA-ISOLEUCINE AND THE JAZ1 DEGRON
198, d5a15M_, 0.5924, 2.83, 0.191, 113, 89, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
199, p3ogmI_, 0.5924, 2.56, 0.140, 95, 86, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND THE JAZ1 DEGRON
200, d5a15C_, 0.5923, 2.49, 0.207, 106, 87, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
201, p3ogmA_, 0.5923, 2.52, 0.195, 106, 87, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND THE JAZ1 DEGRON
202, p3drxE1, 0.5923, 2.86, 0.128, 98, 94, X-RAY CRYSTAL STRUCTURE OF HUMAN KCTD5 PROTEIN CRYSTALLIZED IN HIGH- SALT BUFFER
203, p6gsaC_, 0.5922, 2.55, 0.195, 105, 87, CORE CENTROMERE BINDING FACTOR 3 (CBF3) WITH MONOMERIC NDC10 
204, p6fe8C_, 0.5922, 2.55, 0.184, 105, 87, CRYO-EM STRUCTURE OF THE CORE CENTROMERE BINDING FACTOR 3 COMPLEX 
205, p3ogkA_, 0.5922, 2.52, 0.184, 105, 87, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND AN INCOMPLETE JAZ1 DEGRON
206, d4uesB_, 0.5921, 2.42, 0.128, 103, 86,  
207, p3ogmO_, 0.5921, 2.55, 0.195, 105, 87, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND THE JAZ1 DEGRON
208, p3ogmE_, 0.5921, 2.61, 0.140, 95, 86, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND THE JAZ1 DEGRON
209, p3ogkG_, 0.5921, 2.62, 0.126, 103, 87, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND AN INCOMPLETE JAZ1 DEGRON
210, p3drxA2, 0.5921, 2.42, 0.128, 104, 86, X-RAY CRYSTAL STRUCTURE OF HUMAN KCTD5 PROTEIN CRYSTALLIZED IN HIGH- SALT BUFFER
211, p6c16A_, 0.5919, 2.42, 0.128, 104, 86, UBIQUITIN VARIANT (UBV.FBL10.1) BOUND TO A HUMAN SKP1-FBL11 FRAGMENT COMPLEX. 
212, d5ftaB_, 0.5918, 2.71, 0.205, 106, 88, CRYSTAL STRUCTURE OF THE N-TERMINAL BTB DOMAIN OF HUMAN KCTD10
213, d5bxbH1, 0.5917, 2.54, 0.195, 106, 87, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 1
214, p3ogkI_, 0.5914, 2.55, 0.195, 105, 87, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND AN INCOMPLETE JAZ1 DEGRON
215, d5a15H_, 0.5912, 2.55, 0.195, 105, 87, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
216, p2p1oA_, 0.5912, 2.57, 0.184, 105, 87, MECHANISM OF AUXIN PERCEPTION BY THE TIR1 UBIQUITIN LIGASE
217, p3ogkE_, 0.5910, 2.62, 0.140, 95, 86, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND AN INCOMPLETE JAZ1 DEGRON
218, d5a15K_, 0.5904, 2.53, 0.207, 105, 87, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
219, d5bxdB1, 0.5903, 2.67, 0.182, 107, 88, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 2
220, d5bxbB1, 0.5903, 2.59, 0.140, 95, 86, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 1
221, p3dryD2, 0.5903, 2.58, 0.195, 105, 87, X-RAY CRYSTAL STRUCTURE OF HUMAN KCTD5 PROTEIN CRYSTALLIZED IN LOW- SALT BUFFER
222, d5a15E_, 0.5902, 2.60, 0.140, 95, 86, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
223, d5a15I_, 0.5901, 2.58, 0.195, 105, 87, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
224, d5bxbI1, 0.5899, 2.85, 0.191, 113, 89, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 1
225, d5a15D_, 0.5899, 2.85, 0.191, 113, 89, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
226, d5a15O_, 0.5898, 2.58, 0.182, 118, 88, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
227, d5a15L_, 0.5898, 2.58, 0.182, 118, 88, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
228, d5bxbJ1, 0.5894, 2.64, 0.182, 108, 88, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 1
229, d5bxbC1, 0.5891, 2.79, 0.136, 101, 88, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 1
230, d5bxbD1, 0.5888, 2.81, 0.191, 105, 89, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 1
231, d5a15N_, 0.5888, 2.54, 0.207, 105, 87, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
232, p2e32D_, 0.5886, 2.54, 0.195, 106, 87, STRUCTURAL BASIS FOR SELECTION OF GLYCOSYLATED SUBSTRATE BY SCFFBS1 UBIQUITIN LIGASE
233, d5bxdC1, 0.5881, 2.66, 0.195, 97, 87, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 2
234, d5a15F_, 0.5880, 2.44, 0.148, 107, 88, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
235, d5bxdE1, 0.5876, 2.79, 0.148, 101, 88, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 2
236, d5bxbE1, 0.5869, 2.61, 0.138, 104, 87, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 1
237, p2p1qA_, 0.5862, 2.58, 0.195, 106, 87, MECHANISM OF AUXIN PERCEPTION BY THE TIR1 UBIQUITIN LIGASE
238, d5ftaD_, 0.5859, 2.61, 0.140, 95, 86, CRYSTAL STRUCTURE OF THE N-TERMINAL BTB DOMAIN OF HUMAN KCTD10
239, p2e32B_, 0.5853, 2.03, 0.157, 88, 83, STRUCTURAL BASIS FOR SELECTION OF GLYCOSYLATED SUBSTRATE BY SCFFBS1 UBIQUITIN LIGASE
240, d4uesD_, 0.5852, 2.54, 0.207, 106, 87,  
241, p3drxB2, 0.5850, 2.61, 0.140, 95, 86, X-RAY CRYSTAL STRUCTURE OF HUMAN KCTD5 PROTEIN CRYSTALLIZED IN HIGH- SALT BUFFER
242, d5bxdD1, 0.5840, 2.52, 0.151, 102, 86, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 2
243, p2p1nD_, 0.5840, 2.46, 0.128, 104, 86, MECHANISM OF AUXIN PERCEPTION BY THE TIR1 UBIQUTIN LIGASE
244, d5a15A_, 0.5838, 2.66, 0.195, 103, 87, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
245, d4jghC_, 0.5835, 2.60, 0.140, 95, 86, STRUCTURE OF THE SOCS2-ELONGIN BC COMPLEX BOUND TO AN N-TERMINAL FRAGMENT OF CULLIN5
246, p2p1nA_, 0.5827, 2.63, 0.140, 95, 86, MECHANISM OF AUXIN PERCEPTION BY THE TIR1 UBIQUTIN LIGASE
247, p4wqoC_, 0.5816, 2.50, 0.128, 104, 86, STRUCTURE OF VHL-ELOB-ELOC-CUL2
248, d3drzC_, 0.5802, 2.65, 0.140, 95, 86, X-RAY CRYSTAL STRUCTURE OF THE N-TERMINAL BTB DOMAIN OF HUMAN KCTD5 PROTEIN
249, d3drzD_, 0.5798, 2.52, 0.141, 95, 85, X-RAY CRYSTAL STRUCTURE OF THE N-TERMINAL BTB DOMAIN OF HUMAN KCTD5 PROTEIN
250, p4yy8B1, 0.5796, 2.68, 0.140, 95, 86, CRYSTAL STRUCTURE ANALYSIS OF KELCH PROTEIN FROM PLASMODIUM FALCIPARUM
251, d3drzE_, 0.5792, 2.46, 0.128, 104, 86, X-RAY CRYSTAL STRUCTURE OF THE N-TERMINAL BTB DOMAIN OF HUMAN KCTD5 PROTEIN
252, p3drxD2, 0.5767, 2.47, 0.128, 103, 86, X-RAY CRYSTAL STRUCTURE OF HUMAN KCTD5 PROTEIN CRYSTALLIZED IN HIGH- SALT BUFFER
253, p4zgcB1, 0.5764, 2.47, 0.128, 104, 86, CRYSTAL STRUCTURE ANALYSIS OF KELCH PROTEIN (WITH DISULFIDE BOND) FROM PLASMODIUM FALCIPARUM
254, p5n4wC_, 0.5733, 2.68, 0.140, 95, 86, CRYSTAL STRUCTURE OF THE CUL2-RBX1-ELOBC-VHL UBIQUITIN LIGASE COMPLEX
255, d4crhA1, 0.5724, 2.25, 0.176, 101, 85, CRYSTAL STRUCTURE OF THE BTB-T1 DOMAIN OF HUMAN SHKBP1
256, p5wieB1, 0.5682, 2.82, 0.125, 102, 88, CRYSTAL STRUCTURE OF A KV1.2-2.1 CHIMERA K+ CHANNEL V406W MUTANT IN AN INACTIVATED STATE
257, p6bvbC_, 0.5657, 2.62, 0.140, 95, 86, CRYSTAL STRUCTURE OF HIF-2ALPHA-PVHL-ELONGIN B-ELONGIN C 
258, p5wieH1, 0.5648, 2.45, 0.140, 104, 86, CRYSTAL STRUCTURE OF A KV1.2-2.1 CHIMERA K+ CHANNEL V406W MUTANT IN AN INACTIVATED STATE
259, p3lnmB1, 0.5644, 2.45, 0.128, 103, 86, F233W MUTANT OF THE KV2.1 PADDLE-KV1.2 CHIMERA CHANNEL
260, p6gfxB_, 0.5637, 1.98, 0.159, 85, 82, PVHL:ELOB:ELOC IN COMPLEX WITH MODIFIED HIF-1A CODD PEPTIDE CONTAINING (3R;4S)-3-FLUORO-4-HYDROXYPROLINE (LIGAND 13A) 
261, p4jtaB1, 0.5636, 2.52, 0.174, 99, 86, CRYSTAL STRUCTURE OF KV1.2-2.1 PADDLE CHIMERA CHANNEL IN COMPLEX WITH CHARYBDOTOXIN
262, d1qdvC_, 0.5629, 2.27, 0.153, 101, 85, N-TERMINAL DOMAIN VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-131
263, p3lutB1, 0.5626, 2.52, 0.163, 99, 86, A STRUCTURAL MODEL FOR THE FULL-LENGTH SHAKER POTASSIUM CHANNEL KV1.2
264, p2r9rB1, 0.5625, 2.74, 0.195, 101, 87, SHAKER FAMILY VOLTAGE DEPENDENT POTASSIUM CHANNEL (KV1.2-KV2.1 PADDLE CHIMERA CHANNEL) IN ASSOCIATION WITH BETA SUBUNIT
265, p4jtdB1, 0.5624, 2.86, 0.125, 104, 88, CRYSTAL STRUCTURE OF KV1.2-2.1 PADDLE CHIMERA CHANNEL IN COMPLEX WITH LYS27MET MUTANT OF CHARYBDOTOXIN
266, p3lnmD1, 0.5624, 1.91, 0.198, 88, 81, F233W MUTANT OF THE KV2.1 PADDLE-KV1.2 CHIMERA CHANNEL
267, p2r9rH1, 0.5623, 2.70, 0.140, 95, 86, SHAKER FAMILY VOLTAGE DEPENDENT POTASSIUM CHANNEL (KV1.2-KV2.1 PADDLE CHIMERA CHANNEL) IN ASSOCIATION WITH BETA SUBUNIT
268, p4jtdH1, 0.5621, 2.70, 0.140, 95, 86, CRYSTAL STRUCTURE OF KV1.2-2.1 PADDLE CHIMERA CHANNEL IN COMPLEX WITH LYS27MET MUTANT OF CHARYBDOTOXIN
269, p4jtcB1, 0.5619, 1.76, 0.187, 96, 80, CRYSTAL STRUCTURE OF KV1.2-2.1 PADDLE CHIMERA CHANNEL IN COMPLEX WITH CHARYBDOTOXIN IN CS+
270, p4jtaQ1, 0.5616, 1.91, 0.198, 87, 81, CRYSTAL STRUCTURE OF KV1.2-2.1 PADDLE CHIMERA CHANNEL IN COMPLEX WITH CHARYBDOTOXIN
271, p4ajyC_, 0.5616, 1.87, 0.200, 96, 80, VON HIPPEL-LINDAU PROTEIN-ELONGINB-ELONGINC COMPLEX BOUND TO HIF1- ALPHA PEPTIDE
272, p6fmkK_, 0.5615, 2.59, 0.200, 96, 85, PVHL:ELOB:ELOC IN COMPLEX WITH N-((S)-1-((2S;4R)-4-HYDROXY-2-((4-(4- METHYLTHIAZOL-5-YL)BENZYL)CARBAMOTHIOYL) PYRROLIDIN-1-YL)-1- THIOXOPROPAN-2-YL)ACETAMIDE (LIGAND 4) 
273, d3kvtA_, 0.5614, 2.65, 0.212, 95, 85, TETRAMERIZATION DOMAIN FROM AKV3.1 (SHAW-SUBFAMILY) VOLTAGE-GATED POTASSIUM CHANNEL
274, d1lqbB_, 0.5611, 2.43, 0.160, 92, 81, CRYSTAL STRUCTURE OF A HYDROXYLATED HIF-1 ALPHA PEPTIDE BOUND TO THE PVHL/ELONGIN-C/ELONGIN-B COMPLEX
275, p4jtcH1, 0.5610, 2.43, 0.160, 92, 81, CRYSTAL STRUCTURE OF KV1.2-2.1 PADDLE CHIMERA CHANNEL IN COMPLEX WITH CHARYBDOTOXIN IN CS+
276, p2a79B1, 0.5609, 2.64, 0.212, 97, 85, MAMMALIAN SHAKER KV1.2 POTASSIUM CHANNEL- BETA SUBUNIT COMPLEX
277, d5t35G1, 0.5602, 2.77, 0.209, 101, 86, THE PROTAC MZ1 IN COMPLEX WITH THE SECOND BROMODOMAIN OF BRD4 AND PVHL:ELONGINC:ELONGINB
278, d1t1dA_, 0.5593, 2.41, 0.162, 91, 80, CRYSTAL STRUCTURE OF THE TETRAMERIZATION DOMAIN OF THE SHAKER POTASSIUM CHANNEL
279, d1lm8C_, 0.5593, 2.36, 0.203, 91, 79, STRUCTURE OF A HIF-1A-PVHL-ELONGINB-ELONGINC COMPLEX
280, p6gfzE_, 0.5592, 2.25, 0.215, 93, 79, PVHL:ELOB:ELOC IN COMPLEX WITH MODIFIED VH032 CONTAINING (3S;4S)-3- FLUORO-4-HYDROXYPROLINE (LIGAND 14B) 
281, d3ztdK_, 0.5592, 2.25, 0.215, 93, 79, PVHL54-213-ELOB-ELOC COMPLEX _ METHYL 4-(((2S4R)-4-HYDROXY- 1-(2-(3-METHYLISOXAZOL-5-YL)ACETYL)PYRROLIDINE-2- CARBOXAMIDO)METHYL)BENZOATE
282, d1qdvD_, 0.5589, 3.39, 0.089, 110, 90, N-TERMINAL DOMAIN VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-131
283, d1eofA_, 0.5588, 3.39, 0.089, 110, 90, CRYSTAL STRUCTURE OF THE N136A MUTANT OF A SHAKER T1 DOMAIN
284, p4yy8A1, 0.5582, 1.84, 0.208, 89, 77, CRYSTAL STRUCTURE ANALYSIS OF KELCH PROTEIN FROM PLASMODIUM FALCIPARUM
285, p6gfyE_, 0.5581, 2.85, 0.105, 107, 86, PVHL:ELOB:ELOC IN COMPLEX WITH MODIFIED VH032 CONTAINING (3R;4S)-3- FLUORO-4-HYDROXYPROLINE (LIGAND 14A) 
286, d1vcbE_, 0.5579, 2.86, 0.105, 108, 86, THE VHL-ELONGINC-ELONGINB STRUCTURE
287, d1vcbB_, 0.5578, 1.68, 0.211, 88, 76, THE VHL-ELONGINC-ELONGINB STRUCTURE
288, d1s1gB1, 0.5576, 2.88, 0.105, 105, 86, CRYSTAL STRUCTURE OF KV4.3 T1 DOMAIN
289, d1eodA_, 0.5576, 3.27, 0.091, 99, 88, CRYSTAL STRUCTURE OF THE N136D MUTANT OF A SHAKER T1 DOMAIN
290, p6gfzH_, 0.5571, 2.69, 0.106, 105, 85, PVHL:ELOB:ELOC IN COMPLEX WITH MODIFIED VH032 CONTAINING (3S;4S)-3- FLUORO-4-HYDROXYPROLINE (LIGAND 14B) 
291, d1eoeA_, 0.5571, 2.70, 0.106, 105, 85, CRYSTAL STRUCTURE OF THE V135R MUTANT OF A SHAKER T1 DOMAIN
292, d2fnjC_, 0.5568, 2.72, 0.106, 106, 85, CRYSTAL STRUCTURE OF A B30.2/SPRY DOMAIN-CONTAINING PROTEIN GUSTAVUS IN COMPLEX WITH ELONGIN B AND ELONGIN C
293, d5t35C1, 0.5567, 2.78, 0.094, 100, 85, THE PROTAC MZ1 IN COMPLEX WITH THE SECOND BROMODOMAIN OF BRD4 AND PVHL:ELONGINC:ELONGINB
294, p6gfyK_, 0.5563, 2.76, 0.094, 99, 85, PVHL:ELOB:ELOC IN COMPLEX WITH MODIFIED VH032 CONTAINING (3R;4S)-3- FLUORO-4-HYDROXYPROLINE (LIGAND 14A) 
295, p6fmkE_, 0.5563, 2.79, 0.094, 99, 85, PVHL:ELOB:ELOC IN COMPLEX WITH N-((S)-1-((2S;4R)-4-HYDROXY-2-((4-(4- METHYLTHIAZOL-5-YL)BENZYL)CARBAMOTHIOYL) PYRROLIDIN-1-YL)-1- THIOXOPROPAN-2-YL)ACETAMIDE (LIGAND 4) 
296, d1vcbK_, 0.5562, 2.72, 0.106, 105, 85, THE VHL-ELONGINC-ELONGINB STRUCTURE
297, d3ztdH_, 0.5559, 2.80, 0.094, 99, 85, PVHL54-213-ELOB-ELOC COMPLEX _ METHYL 4-(((2S4R)-4-HYDROXY- 1-(2-(3-METHYLISOXAZOL-5-YL)ACETYL)PYRROLIDINE-2- CARBOXAMIDO)METHYL)BENZOATE
298, p6c5xC_, 0.5558, 1.86, 0.211, 88, 76, CRYSTAL STRUCTURE OF SOCS1 IN COMPLEX WITH ELONGINB AND ELONGINC 
299, p6gfzK_, 0.5557, 1.71, 0.197, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH MODIFIED VH032 CONTAINING (3S;4S)-3- FLUORO-4-HYDROXYPROLINE (LIGAND 14B) 
300, d1vcbH_, 0.5557, 3.13, 0.090, 103, 89, THE VHL-ELONGINC-ELONGINB STRUCTURE
301, d1qdvA_, 0.5555, 3.13, 0.090, 103, 89, N-TERMINAL DOMAIN VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-131
302, p6gfyB_, 0.5554, 1.74, 0.211, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH MODIFIED VH032 CONTAINING (3R;4S)-3- FLUORO-4-HYDROXYPROLINE (LIGAND 14A) 
303, p6fmkB_, 0.5553, 2.79, 0.094, 99, 85, PVHL:ELOB:ELOC IN COMPLEX WITH N-((S)-1-((2S;4R)-4-HYDROXY-2-((4-(4- METHYLTHIAZOL-5-YL)BENZYL)CARBAMOTHIOYL) PYRROLIDIN-1-YL)-1- THIOXOPROPAN-2-YL)ACETAMIDE (LIGAND 4) 
304, d4bgcA1, 0.5553, 2.77, 0.094, 99, 85, T1 DOMAIN OF THE RENAL POTASSIUM CHANNEL KV1.3
305, d5nw1E1, 0.5552, 1.69, 0.213, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2- (CYCLOBUTANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 18)
306, p2nz0D_, 0.5552, 3.17, 0.115, 100, 87, CRYSTAL STRUCTURE OF POTASSIUM CHANNEL KV4.3 IN COMPLEX WITH ITS REGULATORY SUBUNIT KCHIP1 (CASP TARGET)
307, p6gfzB_, 0.5550, 1.83, 0.211, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH MODIFIED VH032 CONTAINING (3S;4S)-3- FLUORO-4-HYDROXYPROLINE (LIGAND 14B) 
308, p6fmjK_, 0.5550, 2.13, 0.218, 91, 78, PVHL:ELOB:ELOC IN COMPLEX WITH (2S;4R)-1-((S)-2- ACETAMIDOPROPANETHIOYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL) BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 3) 
309, d3zunH_, 0.5550, 1.67, 0.213, 87, 75, PVHL54-213-ELOB-ELOC COMPLEX_(2S4R)-4-HYDROXY-1-(2-(3- METHYLISOXAZOL-5-YL)ACETYL)-N-(4-NITROBENZYL)PYRROLIDINE-2- CARBOXAMIDE BOUND
310, d1qdvB_, 0.5548, 2.70, 0.095, 99, 84, N-TERMINAL DOMAIN VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-131
311, d4w9gE_, 0.5545, 3.02, 0.128, 100, 86, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(3-METHYL-4-(THIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 6)
312, p6fmjE_, 0.5543, 1.88, 0.160, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S;4R)-1-((S)-2- ACETAMIDOPROPANETHIOYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL) BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 3) 
313, d5lliE1, 0.5543, 2.17, 0.192, 91, 78, PVHL:ELOB:ELOC IN COMPLEX WITH VH298
314, d3dcgD_, 0.5543, 1.98, 0.211, 88, 76, CRYSTAL STRUCTURE OF THE HIV VIF BC-BOX IN COMPLEX WITH HUMAN ELONGINB AND ELONGINC
315, p6fmiB_, 0.5541, 1.99, 0.211, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH N-((S)-1-((2S;4R)-4-HYDROXY-2-((4-(4- METHYLTHIAZOL-5-YL)BENZYL)CARBAMOTHIOYL) PYRROLIDIN-1-YL)-1- OXOPROPAN-2-YL)ACETAMIDE (LIGAND 2) 
316, d3zunE_, 0.5541, 3.09, 0.170, 108, 88, PVHL54-213-ELOB-ELOC COMPLEX_(2S4R)-4-HYDROXY-1-(2-(3- METHYLISOXAZOL-5-YL)ACETYL)-N-(4-NITROBENZYL)PYRROLIDINE-2- CARBOXAMIDE BOUND
317, d4w9lH_, 0.5540, 3.09, 0.170, 108, 88, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-((S)-2-ACETAMIDO-33- DIMETHYLBUTANAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 15)
318, d5nw0E1, 0.5538, 3.12, 0.115, 100, 87, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-(1- ACETAMIDOCYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N- (4-(4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 17)
319, d4w9gH_, 0.5538, 1.91, 0.208, 89, 77, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(3-METHYL-4-(THIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 6)
320, d3zrcE_, 0.5538, 3.15, 0.126, 100, 87, PVHL54-213-ELOB-ELOC COMPLEX (4R)-4-HYDROXY-1-[(3-METHYLISOXAZOL-5- YL)ACETYL]-N-[4-(13-OXAZOL-5-YL)BENZYL]-L-PROLINAMIDE BOUND
321, d5nw2E1, 0.5536, 1.72, 0.213, 88, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-33-DIMETHYL-2-(OXETANE- 3-CARBOXAMIDO)BUTANOYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE (LIGAND 19)
322, d5nw1H1, 0.5535, 1.61, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2- (CYCLOBUTANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 18)
323, p6gfyH_, 0.5534, 1.77, 0.197, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH MODIFIED VH032 CONTAINING (3R;4S)-3- FLUORO-4-HYDROXYPROLINE (LIGAND 14A) 
324, d5nw2H1, 0.5534, 2.22, 0.205, 91, 78, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-33-DIMETHYL-2-(OXETANE- 3-CARBOXAMIDO)BUTANOYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE (LIGAND 19)
325, d4w9dK1, 0.5534, 2.00, 0.211, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(4-METHYLOXAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 3)
326, p6fmjB_, 0.5532, 1.72, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S;4R)-1-((S)-2- ACETAMIDOPROPANETHIOYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL) BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 3) 
327, d4w9lE_, 0.5532, 1.61, 0.203, 83, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-((S)-2-ACETAMIDO-33- DIMETHYLBUTANAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 15)
328, d4w9gK1, 0.5532, 1.78, 0.184, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(3-METHYL-4-(THIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 6)
329, d4bksB_, 0.5532, 2.00, 0.211, 88, 76, VON HIPPEL LINDAU PROTEIN:ELONGINB:ELONGINC COMPLEX IN COMPLEX WITH (2S4R)-1-ETHANOYL-N-[[4-(13-OXAZOL-5-YL)PHENYL]METHYL]-4-OXIDANYL- PYRROLIDINE-2-CARBOXAMIDE
330, d5nw0K1, 0.5531, 2.81, 0.095, 99, 84, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-(1- ACETAMIDOCYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N- (4-(4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 17)
331, d4w9eE_, 0.5531, 1.69, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(THIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 4)
332, d4b95B1, 0.5531, 1.71, 0.200, 87, 75, PVHL-ELOB-ELOB-ELOCC COMPLEX_(2S4R)-1-(2-CHLOROPHENYL)CARBONYL-N-[ (4-CHLOROPHENYL)METHYL]-4-OXIDANYL-PYRROLIDINE-2-CARBOXAMIDE BOUND
333, d5nw2K1, 0.5530, 2.87, 0.083, 100, 84, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-33-DIMETHYL-2-(OXETANE- 3-CARBOXAMIDO)BUTANOYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE (LIGAND 19)
334, d4w9cH_, 0.5530, 2.12, 0.221, 90, 77, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(OXAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 2)
335, d4w9cE_, 0.5530, 3.04, 0.140, 105, 86, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(OXAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 2)
336, d3ztcH_, 0.5530, 1.68, 0.200, 87, 75, PVHL54-213-ELOB-ELOC COMPLEX _ (2S4R)-N-((11 -BIPHENYL)-4- YLMETHYL)-4-HYDROXY-1-(2-(3-METHYLISOXAZOL-5-YL)ACETYL) PYRROLIDINE-2-CARBOXAMIDE
337, d3zunB_, 0.5529, 1.80, 0.184, 88, 76, PVHL54-213-ELOB-ELOC COMPLEX_(2S4R)-4-HYDROXY-1-(2-(3- METHYLISOXAZOL-5-YL)ACETYL)-N-(4-NITROBENZYL)PYRROLIDINE-2- CARBOXAMIDE BOUND
338, d3ztdE_, 0.5529, 1.73, 0.213, 87, 75, PVHL54-213-ELOB-ELOC COMPLEX _ METHYL 4-(((2S4R)-4-HYDROXY- 1-(2-(3-METHYLISOXAZOL-5-YL)ACETYL)PYRROLIDINE-2- CARBOXAMIDO)METHYL)BENZOATE
339, d4w9dE_, 0.5528, 2.74, 0.095, 99, 84, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(4-METHYLOXAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 3)
340, d5nvzE1, 0.5527, 1.89, 0.224, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-(1- ACETYLCYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4- (4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 16)
341, d4w9kH_, 0.5526, 2.29, 0.205, 91, 78, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-((S)-2-ACETAMIDO-3- PHENYLPROPANAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 14)
342, d5nw1K1, 0.5525, 2.15, 0.221, 90, 77, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2- (CYCLOBUTANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 18)
343, d4w9dH_, 0.5525, 1.62, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(4-METHYLOXAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 3)
344, d3zrcB_, 0.5525, 1.61, 0.203, 86, 74, PVHL54-213-ELOB-ELOC COMPLEX (4R)-4-HYDROXY-1-[(3-METHYLISOXAZOL-5- YL)ACETYL]-N-[4-(13-OXAZOL-5-YL)BENZYL]-L-PROLINAMIDE BOUND
345, p6fmjH_, 0.5524, 1.76, 0.213, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S;4R)-1-((S)-2- ACETAMIDOPROPANETHIOYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL) BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 3) 
346, d4w9jH_, 0.5524, 1.89, 0.197, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-((S)-2-ACETAMIDO-4- METHYLPENTANAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 13)
347, d3zrfB_, 0.5524, 2.17, 0.221, 90, 77, PVHL54-213-ELOB-ELOC COMPLEX_APO
348, d5lliK1, 0.5523, 1.89, 0.211, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH VH298
349, d5lliH1, 0.5523, 1.77, 0.213, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH VH298
350, d4b95H1, 0.5523, 2.16, 0.221, 90, 77, PVHL-ELOB-ELOB-ELOCC COMPLEX_(2S4R)-1-(2-CHLOROPHENYL)CARBONYL-N-[ (4-CHLOROPHENYL)METHYL]-4-OXIDANYL-PYRROLIDINE-2-CARBOXAMIDE BOUND
351, d3zunK_, 0.5522, 1.91, 0.224, 88, 76, PVHL54-213-ELOB-ELOC COMPLEX_(2S4R)-4-HYDROXY-1-(2-(3- METHYLISOXAZOL-5-YL)ACETYL)-N-(4-NITROBENZYL)PYRROLIDINE-2- CARBOXAMIDE BOUND
352, d4w9kE_, 0.5521, 1.98, 0.208, 89, 77, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-((S)-2-ACETAMIDO-3- PHENYLPROPANAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 14)
353, d5nvzK1, 0.5520, 1.90, 0.211, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-(1- ACETYLCYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4- (4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 16)
354, d4w9jE_, 0.5520, 1.71, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-((S)-2-ACETAMIDO-4- METHYLPENTANAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 13)
355, d4bktB_, 0.5520, 1.71, 0.200, 87, 75, VON HIPPEL LINDAU PROTEIN:ELONGINB:ELONGINC COMPLEX IN COMPLEX WITH (2S4R)-N-METHYL-1-[2-(3-METHYL-12-OXAZOL-5-YL)ETHANOYL]-4-OXIDANYL- PYRROLIDINE-2-CARBOXAMIDE
356, p6fmkH_, 0.5519, 1.90, 0.224, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH N-((S)-1-((2S;4R)-4-HYDROXY-2-((4-(4- METHYLTHIAZOL-5-YL)BENZYL)CARBAMOTHIOYL) PYRROLIDIN-1-YL)-1- THIOXOPROPAN-2-YL)ACETAMIDE (LIGAND 4) 
357, p2nz0B_, 0.5519, 1.71, 0.200, 87, 75, CRYSTAL STRUCTURE OF POTASSIUM CHANNEL KV4.3 IN COMPLEX WITH ITS REGULATORY SUBUNIT KCHIP1 (CASP TARGET)
358, d4w9iE_, 0.5518, 1.75, 0.213, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((2S4R)-1-ACETYL-4- HYDROXYPYRROLIDINE-2-CARBONYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL) BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 10)
359, p4n9fB_, 0.5518, 1.73, 0.200, 87, 75, CRYSTAL STRUCTURE OF THE VIF-CBFBETA-CUL5-ELOB-ELOC PENTAMERIC COMPLEX
360, d4w9cK1, 0.5517, 1.91, 0.224, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(OXAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 2)
361, d3ztcB_, 0.5517, 1.62, 0.203, 86, 74, PVHL54-213-ELOB-ELOC COMPLEX _ (2S4R)-N-((11 -BIPHENYL)-4- YLMETHYL)-4-HYDROXY-1-(2-(3-METHYLISOXAZOL-5-YL)ACETYL) PYRROLIDINE-2-CARBOXAMIDE
362, d5nw0H1, 0.5516, 1.73, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-(1- ACETAMIDOCYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N- (4-(4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 17)
363, d4w9eK1, 0.5516, 1.90, 0.211, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(THIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 4)
364, d3zrfE_, 0.5516, 1.93, 0.224, 88, 76, PVHL54-213-ELOB-ELOC COMPLEX_APO
365, d3dcgB_, 0.5515, 1.76, 0.200, 86, 75, CRYSTAL STRUCTURE OF THE HIV VIF BC-BOX IN COMPLEX WITH HUMAN ELONGINB AND ELONGINC
366, d5nvxH1, 0.5514, 1.64, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-(1- FLUOROCYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4- (4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 10)
367, d4w9jK1, 0.5514, 1.77, 0.213, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-((S)-2-ACETAMIDO-4- METHYLPENTANAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 13)
368, d3zrcK_, 0.5514, 1.93, 0.224, 88, 76, PVHL54-213-ELOB-ELOC COMPLEX (4R)-4-HYDROXY-1-[(3-METHYLISOXAZOL-5- YL)ACETYL]-N-[4-(13-OXAZOL-5-YL)BENZYL]-L-PROLINAMIDE BOUND
369, d1s1gA1, 0.5514, 2.19, 0.195, 90, 77, CRYSTAL STRUCTURE OF KV4.3 T1 DOMAIN
370, d5nvvH1, 0.5513, 1.92, 0.197, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-4-HYDROXY-1-((S)-2-(2- HYDROXYACETAMIDO)-33-DIMETHYLBUTANOYL)-N-(4-(4-METHYLTHIAZOL-5-YL) BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 3)
371, d5bo4I1, 0.5513, 1.74, 0.200, 87, 75, STRUCTURE OF SOCS2:ELONGIN C:ELONGIN B FROM DMSO-TREATED CRYSTALS
372, d5nvzH1, 0.5512, 1.90, 0.211, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-(1- ACETYLCYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4- (4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 16)
373, d4w9iH_, 0.5512, 1.65, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((2S4R)-1-ACETYL-4- HYDROXYPYRROLIDINE-2-CARBONYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL) BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 10)
374, d3ztdB_, 0.5512, 1.97, 0.221, 89, 77, PVHL54-213-ELOB-ELOC COMPLEX _ METHYL 4-(((2S4R)-4-HYDROXY- 1-(2-(3-METHYLISOXAZOL-5-YL)ACETYL)PYRROLIDINE-2- CARBOXAMIDO)METHYL)BENZOATE
375, d4w9kK1, 0.5510, 1.92, 0.197, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-((S)-2-ACETAMIDO-3- PHENYLPROPANAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 14)
376, p4n9ft_, 0.5510, 1.64, 0.203, 86, 74, CRYSTAL STRUCTURE OF THE VIF-CBFBETA-CUL5-ELOB-ELOC PENTAMERIC COMPLEX
377, p4n9fE_, 0.5509, 1.74, 0.200, 87, 75, CRYSTAL STRUCTURE OF THE VIF-CBFBETA-CUL5-ELOB-ELOC PENTAMERIC COMPLEX
378, d4bktH_, 0.5509, 1.91, 0.211, 88, 76, VON HIPPEL LINDAU PROTEIN:ELONGINB:ELONGINC COMPLEX IN COMPLEX WITH (2S4R)-N-METHYL-1-[2-(3-METHYL-12-OXAZOL-5-YL)ETHANOYL]-4-OXIDANYL- PYRROLIDINE-2-CARBOXAMIDE
379, d4w9iK1, 0.5508, 1.65, 0.216, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((2S4R)-1-ACETYL-4- HYDROXYPYRROLIDINE-2-CARBONYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL) BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 10)
380, d4awjB_, 0.5508, 1.63, 0.203, 86, 74, PVHL:ELOB:ELOC COMPLEX IN COMPLEX WITH CAPPED HYDROXYPROLINE
381, d5nvyK1, 0.5507, 1.92, 0.224, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-ACETAMIDOPROPANOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE (LIGAND 11)
382, d4b9kB1, 0.5507, 1.74, 0.200, 87, 75, PVHL-ELOB-ELOC COMPLEX_(2S4R)-1-(3-AMINO-2-METHYLBENZOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE BOUND
383, d5nvwH1, 0.5506, 1.89, 0.224, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2- (CYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 6)
384, d4awjH_, 0.5506, 1.76, 0.200, 87, 75, PVHL:ELOB:ELOC COMPLEX IN COMPLEX WITH CAPPED HYDROXYPROLINE
385, d5nvyH1, 0.5504, 2.01, 0.208, 89, 77, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-ACETAMIDOPROPANOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE (LIGAND 11)
386, p4zgcA1, 0.5504, 2.91, 0.141, 104, 85, CRYSTAL STRUCTURE ANALYSIS OF KELCH PROTEIN (WITH DISULFIDE BOND) FROM PLASMODIUM FALCIPARUM
387, d3ztcK_, 0.5504, 1.92, 0.224, 88, 76, PVHL54-213-ELOB-ELOC COMPLEX _ (2S4R)-N-((11 -BIPHENYL)-4- YLMETHYL)-4-HYDROXY-1-(2-(3-METHYLISOXAZOL-5-YL)ACETYL) PYRROLIDINE-2-CARBOXAMIDE
388, d3ztcE_, 0.5504, 1.88, 0.213, 87, 75, PVHL54-213-ELOB-ELOC COMPLEX _ (2S4R)-N-((11 -BIPHENYL)-4- YLMETHYL)-4-HYDROXY-1-(2-(3-METHYLISOXAZOL-5-YL)ACETYL) PYRROLIDINE-2-CARBOXAMIDE
389, d4w9gB_, 0.5503, 1.73, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(3-METHYL-4-(THIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 6)
390, d4awjE_, 0.5502, 1.66, 0.203, 86, 74, PVHL:ELOB:ELOC COMPLEX IN COMPLEX WITH CAPPED HYDROXYPROLINE
391, d5nvyE1, 0.5501, 1.92, 0.211, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-ACETAMIDOPROPANOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE (LIGAND 11)
392, d4w9eH_, 0.5501, 1.73, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(THIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 4)
393, d5nw1B1, 0.5500, 1.82, 0.213, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2- (CYCLOBUTANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 18)
394, d5nvxK1, 0.5499, 1.67, 0.203, 84, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-(1- FLUOROCYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4- (4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 10)
395, d4w9lB_, 0.5499, 1.92, 0.211, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-((S)-2-ACETAMIDO-33- DIMETHYLBUTANAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 15)
396, d4w9dB_, 0.5499, 1.74, 0.187, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(4-METHYLOXAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 3)
397, p2i2rC_, 0.5499, 1.78, 0.213, 87, 75, CRYSTAL STRUCTURE OF THE KCHIP1/KV4.3 T1 COMPLEX
398, p2i2rA_, 0.5499, 3.03, 0.140, 105, 86, CRYSTAL STRUCTURE OF THE KCHIP1/KV4.3 T1 COMPLEX
399, d5nw0B1, 0.5498, 1.93, 0.211, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-(1- ACETAMIDOCYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N- (4-(4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 17)
400, d5nvxE1, 0.5498, 1.78, 0.213, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-(1- FLUOROCYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4- (4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 10)
401, d4bksH_, 0.5498, 1.94, 0.197, 88, 76, VON HIPPEL LINDAU PROTEIN:ELONGINB:ELONGINC COMPLEX IN COMPLEX WITH (2S4R)-1-ETHANOYL-N-[[4-(13-OXAZOL-5-YL)PHENYL]METHYL]-4-OXIDANYL- PYRROLIDINE-2-CARBOXAMIDE
402, d5nvyB1, 0.5497, 1.90, 0.211, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-ACETAMIDOPROPANOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE (LIGAND 11)
403, d4w9kB_, 0.5497, 1.66, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-((S)-2-ACETAMIDO-3- PHENYLPROPANAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 14)
404, p4n9f5_, 0.5497, 1.75, 0.187, 87, 75, CRYSTAL STRUCTURE OF THE VIF-CBFBETA-CUL5-ELOB-ELOC PENTAMERIC COMPLEX
405, d4bksE_, 0.5497, 1.96, 0.213, 87, 75, VON HIPPEL LINDAU PROTEIN:ELONGINB:ELONGINC COMPLEX IN COMPLEX WITH (2S4R)-1-ETHANOYL-N-[[4-(13-OXAZOL-5-YL)PHENYL]METHYL]-4-OXIDANYL- PYRROLIDINE-2-CARBOXAMIDE
406, p2i2rI_, 0.5496, 1.90, 0.213, 87, 75, CRYSTAL STRUCTURE OF THE KCHIP1/KV4.3 T1 COMPLEX
407, d4b95E1, 0.5495, 1.83, 0.213, 87, 75, PVHL-ELOB-ELOB-ELOCC COMPLEX_(2S4R)-1-(2-CHLOROPHENYL)CARBONYL-N-[ (4-CHLOROPHENYL)METHYL]-4-OXIDANYL-PYRROLIDINE-2-CARBOXAMIDE BOUND
408, d3zrfH_, 0.5495, 1.77, 0.187, 87, 75, PVHL54-213-ELOB-ELOC COMPLEX_APO
409, p2i2rL2, 0.5495, 1.79, 0.200, 87, 75, CRYSTAL STRUCTURE OF THE KCHIP1/KV4.3 T1 COMPLEX
410, d5nvwE1, 0.5494, 1.75, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2- (CYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 6)
411, d4w9hK1, 0.5494, 1.78, 0.213, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-ACETAMIDO-33- DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE (LIGAND 7)
412, p2i2rJ_, 0.5494, 1.91, 0.211, 88, 76, CRYSTAL STRUCTURE OF THE KCHIP1/KV4.3 T1 COMPLEX
413, p2i2rD_, 0.5494, 1.80, 0.213, 87, 75, CRYSTAL STRUCTURE OF THE KCHIP1/KV4.3 T1 COMPLEX
414, d5nvvE1, 0.5492, 1.94, 0.211, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-4-HYDROXY-1-((S)-2-(2- HYDROXYACETAMIDO)-33-DIMETHYLBUTANOYL)-N-(4-(4-METHYLTHIAZOL-5-YL) BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 3)
415, p2i2rK_, 0.5492, 1.87, 0.149, 85, 74, CRYSTAL STRUCTURE OF THE KCHIP1/KV4.3 T1 COMPLEX
416, d5nvvK1, 0.5491, 1.83, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-4-HYDROXY-1-((S)-2-(2- HYDROXYACETAMIDO)-33-DIMETHYLBUTANOYL)-N-(4-(4-METHYLTHIAZOL-5-YL) BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 3)
417, d4w9jB_, 0.5491, 1.86, 0.213, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-((S)-2-ACETAMIDO-4- METHYLPENTANAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 13)
418, d1nn7A_, 0.5491, 1.66, 0.203, 86, 74, CRYSTAL STRUCTURE OF THE TETRAMERIZATION DOMAIN OF THE SHAL VOLTAGE- GATED POTASSIUM CHANNEL
419, d5nw2B1, 0.5490, 1.81, 0.213, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-33-DIMETHYL-2-(OXETANE- 3-CARBOXAMIDO)BUTANOYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE (LIGAND 19)
420, d5lliB1, 0.5490, 2.21, 0.195, 90, 77, PVHL:ELOB:ELOC IN COMPLEX WITH VH298
421, d5nvzB1, 0.5489, 1.93, 0.211, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-(1- ACETYLCYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4- (4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 16)
422, d5nvwB1, 0.5489, 1.67, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2- (CYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 6)
423, d4w9cB_, 0.5489, 1.78, 0.187, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(OXAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 2)
424, p4n9fZ_, 0.5489, 1.66, 0.203, 86, 74, CRYSTAL STRUCTURE OF THE VIF-CBFBETA-CUL5-ELOB-ELOC PENTAMERIC COMPLEX
425, d4b9kK1, 0.5489, 1.67, 0.203, 86, 74, PVHL-ELOB-ELOC COMPLEX_(2S4R)-1-(3-AMINO-2-METHYLBENZOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE BOUND
426, p6fmiE_, 0.5488, 3.15, 0.140, 102, 86, PVHL:ELOB:ELOC IN COMPLEX WITH N-((S)-1-((2S;4R)-4-HYDROXY-2-((4-(4- METHYLTHIAZOL-5-YL)BENZYL)CARBAMOTHIOYL) PYRROLIDIN-1-YL)-1- OXOPROPAN-2-YL)ACETAMIDE (LIGAND 2) 
427, d5nvwK1, 0.5488, 3.16, 0.140, 104, 86, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2- (CYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 6)
428, d5nvxB1, 0.5486, 1.67, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-(1- FLUOROCYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4- (4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 10)
429, d4w9eB_, 0.5485, 2.19, 0.208, 90, 77, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(THIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 4)
430, d3zrcH_, 0.5485, 1.84, 0.213, 87, 75, PVHL54-213-ELOB-ELOC COMPLEX (4R)-4-HYDROXY-1-[(3-METHYLISOXAZOL-5- YL)ACETYL]-N-[4-(13-OXAZOL-5-YL)BENZYL]-L-PROLINAMIDE BOUND
431, d4bktE_, 0.5484, 1.67, 0.203, 86, 74, VON HIPPEL LINDAU PROTEIN:ELONGINB:ELONGINC COMPLEX IN COMPLEX WITH (2S4R)-N-METHYL-1-[2-(3-METHYL-12-OXAZOL-5-YL)ETHANOYL]-4-OXIDANYL- PYRROLIDINE-2-CARBOXAMIDE
432, d4w9iB_, 0.5483, 1.66, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((2S4R)-1-ACETYL-4- HYDROXYPYRROLIDINE-2-CARBONYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL) BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 10)
433, d2izvC_, 0.5483, 1.93, 0.213, 87, 75, CRYSTAL STRUCTURE OF SOCS-4 IN COMPLEX WITH ELONGIN-B AND ELONGIN-C AT 2.55A RESOLUTION
434, p4n9fQ_, 0.5482, 1.84, 0.200, 87, 75, CRYSTAL STRUCTURE OF THE VIF-CBFBETA-CUL5-ELOB-ELOC PENTAMERIC COMPLEX
435, p4n9fn_, 0.5480, 3.15, 0.140, 103, 86, CRYSTAL STRUCTURE OF THE VIF-CBFBETA-CUL5-ELOB-ELOC PENTAMERIC COMPLEX
436, p4n9fY_, 0.5476, 1.73, 0.203, 86, 74, CRYSTAL STRUCTURE OF THE VIF-CBFBETA-CUL5-ELOB-ELOC PENTAMERIC COMPLEX
437, d5nvvB1, 0.5472, 1.68, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-4-HYDROXY-1-((S)-2-(2- HYDROXYACETAMIDO)-33-DIMETHYLBUTANOYL)-N-(4-(4-METHYLTHIAZOL-5-YL) BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 3)
438, d4w9lK1, 0.5471, 3.15, 0.140, 102, 86, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-((S)-2-ACETAMIDO-33- DIMETHYLBUTANAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 15)
439, d4bktK1, 0.5471, 2.20, 0.208, 90, 77, VON HIPPEL LINDAU PROTEIN:ELONGINB:ELONGINC COMPLEX IN COMPLEX WITH (2S4R)-N-METHYL-1-[2-(3-METHYL-12-OXAZOL-5-YL)ETHANOYL]-4-OXIDANYL- PYRROLIDINE-2-CARBOXAMIDE
440, p2i2rB_, 0.5470, 1.77, 0.187, 87, 75, CRYSTAL STRUCTURE OF THE KCHIP1/KV4.3 T1 COMPLEX
441, d4b9kH_, 0.5469, 3.15, 0.140, 104, 86, PVHL-ELOB-ELOC COMPLEX_(2S4R)-1-(3-AMINO-2-METHYLBENZOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE BOUND
442, p4n9fz_, 0.5467, 3.15, 0.140, 102, 86, CRYSTAL STRUCTURE OF THE VIF-CBFBETA-CUL5-ELOB-ELOC PENTAMERIC COMPLEX
443, p4n9fh_, 0.5465, 2.24, 0.195, 90, 77, CRYSTAL STRUCTURE OF THE VIF-CBFBETA-CUL5-ELOB-ELOC PENTAMERIC COMPLEX
444, p4n9fK_, 0.5463, 3.15, 0.140, 104, 86, CRYSTAL STRUCTURE OF THE VIF-CBFBETA-CUL5-ELOB-ELOC PENTAMERIC COMPLEX
445, d4w9hH_, 0.5445, 1.78, 0.187, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-ACETAMIDO-33- DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE (LIGAND 7)
446, d3zngE_, 0.5444, 1.67, 0.203, 86, 74, ANKYRIN REPEAT AND SOCS-BOX PROTEIN 9 (ASB9) IN COMPLEX WITH ELONGINB AND ELONGINC
447, d3zkjB_, 0.5442, 2.97, 0.129, 105, 85, CRYSTAL STRUCTURE OF ANKYRIN REPEAT AND SOCS BOX-CONTAINING PROTEIN 9 (ASB9) IN COMPLEX WITH ELONGINB AND ELONGINC
448, d5bo4O_, 0.5434, 1.68, 0.203, 86, 74, STRUCTURE OF SOCS2:ELONGIN C:ELONGIN B FROM DMSO-TREATED CRYSTALS
449, p4n9fT_, 0.5430, 1.68, 0.203, 86, 74, CRYSTAL STRUCTURE OF THE VIF-CBFBETA-CUL5-ELOB-ELOC PENTAMERIC COMPLEX
450, d4b95K1, 0.5428, 1.69, 0.203, 86, 74, PVHL-ELOB-ELOB-ELOCC COMPLEX_(2S4R)-1-(2-CHLOROPHENYL)CARBONYL-N-[ (4-CHLOROPHENYL)METHYL]-4-OXIDANYL-PYRROLIDINE-2-CARBOXAMIDE BOUND
451, d4w9hE_, 0.5427, 1.67, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-ACETAMIDO-33- DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE (LIGAND 7)
452, d2xaiB_, 0.5426, 1.68, 0.203, 86, 74,  
453, d5bo4R_, 0.5425, 2.00, 0.213, 87, 75, STRUCTURE OF SOCS2:ELONGIN C:ELONGIN B FROM DMSO-TREATED CRYSTALS
454, d3zrfK_, 0.5424, 2.01, 0.221, 90, 77, PVHL54-213-ELOB-ELOC COMPLEX_APO
455, d4awjK1, 0.5414, 1.69, 0.203, 86, 74, PVHL:ELOB:ELOC COMPLEX IN COMPLEX WITH CAPPED HYDROXYPROLINE
456, d3zngB_, 0.5414, 1.79, 0.187, 87, 75, ANKYRIN REPEAT AND SOCS-BOX PROTEIN 9 (ASB9) IN COMPLEX WITH ELONGINB AND ELONGINC
457, d4w9fB1, 0.5410, 1.68, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 5)
458, d4w9fE_, 0.5407, 1.68, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 5)
459, d4w9hB_, 0.5402, 1.69, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-ACETAMIDO-33- DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE (LIGAND 7)
460, d4b9kE_, 0.5391, 1.87, 0.200, 87, 75, PVHL-ELOB-ELOC COMPLEX_(2S4R)-1-(3-AMINO-2-METHYLBENZOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE BOUND
461, d3zkjE_, 0.5374, 1.68, 0.203, 86, 74, CRYSTAL STRUCTURE OF ANKYRIN REPEAT AND SOCS BOX-CONTAINING PROTEIN 9 (ASB9) IN COMPLEX WITH ELONGINB AND ELONGINC
462, d2c9wC_, 0.5373, 1.59, 0.205, 85, 73, CRYSTAL STRUCTURE OF SOCS-2 IN COMPLEX WITH ELONGIN-B AND ELONGIN-C AT 1.9A RESOLUTION
463, d4w9fH_, 0.5364, 2.02, 0.213, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 5)
464, d5bo4C1, 0.5363, 1.95, 0.213, 87, 75, STRUCTURE OF SOCS2:ELONGIN C:ELONGIN B FROM DMSO-TREATED CRYSTALS
465, d5bo4F_, 0.5359, 1.93, 0.213, 87, 75, STRUCTURE OF SOCS2:ELONGIN C:ELONGIN B FROM DMSO-TREATED CRYSTALS
466, d2xaiE_, 0.5358, 1.70, 0.203, 86, 74,  
467, d4bksK1, 0.5352, 1.71, 0.189, 86, 74, VON HIPPEL LINDAU PROTEIN:ELONGINB:ELONGINC COMPLEX IN COMPLEX WITH (2S4R)-1-ETHANOYL-N-[[4-(13-OXAZOL-5-YL)PHENYL]METHYL]-4-OXIDANYL- PYRROLIDINE-2-CARBOXAMIDE
468, d5bo4L1, 0.5324, 1.74, 0.203, 86, 74, STRUCTURE OF SOCS2:ELONGIN C:ELONGIN B FROM DMSO-TREATED CRYSTALS
469, d4w9fK1, 0.5321, 2.81, 0.167, 102, 84, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 5)
470, d1exbE_, 0.5311, 2.00, 0.221, 89, 77, STRUCTURE OF THE CYTOPLASMIC BETA SUBUNIT-T1 ASSEMBLY OF VOLTAGE-DEPENDENT K CHANNELS
471, p6c5xF_, 0.5306, 1.99, 0.213, 87, 75, CRYSTAL STRUCTURE OF SOCS1 IN COMPLEX WITH ELONGINB AND ELONGINC 
472, d2jz3C_, 0.5241, 1.96, 0.213, 87, 75, SOCS BOX ELONGINBC TERNARY COMPLEX
473, d1dsxH_, 0.5190, 1.84, 0.216, 86, 74, KV1.2 T1 DOMAIN RESIDUES 33-119 T46V MUTANT
474, d1dsxG_, 0.5181, 1.98, 0.211, 88, 76, KV1.2 T1 DOMAIN RESIDUES 33-119 T46V MUTANT
475, d1dsxF_, 0.5160, 1.54, 0.208, 84, 72, KV1.2 T1 DOMAIN RESIDUES 33-119 T46V MUTANT
476, d1qdwH_, 0.5159, 1.54, 0.208, 82, 72, N-TERMINAL DOMAIN VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-119
477, d1qdwG_, 0.5158, 1.66, 0.192, 79, 73, N-TERMINAL DOMAIN VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-119
478, d1qdwF_, 0.5150, 2.08, 0.213, 87, 75, N-TERMINAL DOMAIN VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-119
479, d1dsxA_, 0.5150, 1.55, 0.208, 84, 72, KV1.2 T1 DOMAIN RESIDUES 33-119 T46V MUTANT
480, d1dsxE_, 0.5149, 1.97, 0.227, 87, 75, KV1.2 T1 DOMAIN RESIDUES 33-119 T46V MUTANT
481, d1qdwE_, 0.5140, 1.56, 0.208, 82, 72, N-TERMINAL DOMAIN VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-119
482, d1dsxD_, 0.5140, 1.66, 0.192, 80, 73, KV1.2 T1 DOMAIN RESIDUES 33-119 T46V MUTANT
483, d1dsxC_, 0.5137, 1.67, 0.205, 85, 73, KV1.2 T1 DOMAIN RESIDUES 33-119 T46V MUTANT
484, d1qdwD_, 0.5136, 1.68, 0.205, 85, 73, N-TERMINAL DOMAIN VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-119
485, d1qdwC_, 0.5130, 1.56, 0.208, 84, 72, N-TERMINAL DOMAIN VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-119
486, d1qdwA_, 0.5125, 1.68, 0.205, 85, 73, N-TERMINAL DOMAIN VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-119
487, d1dsxB_, 0.5120, 1.83, 0.216, 86, 74, KV1.2 T1 DOMAIN RESIDUES 33-119 T46V MUTANT
488, d1a68A_, 0.5120, 1.69, 0.205, 85, 73, CRYSTAL STRUCTURE OF THE TETRAMERIZATION DOMAIN OF THE SHAKER POTASSIUM CHANNEL
489, d1qdwB_, 0.5108, 1.88, 0.203, 86, 74, N-TERMINAL DOMAIN VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-119
490, p3htmD2, 0.5053, 1.53, 0.211, 81, 71, STRUCTURES OF SPOP-SUBSTRATE COMPLEXES: INSIGHTS INTO MOLECULAR ARCHITECTURES OF BTB-CUL3 UBIQUITIN LIGASES: SPOPBTB/3-BOX
491, p3htmB2, 0.5047, 1.64, 0.194, 80, 72, STRUCTURES OF SPOP-SUBSTRATE COMPLEXES: INSIGHTS INTO MOLECULAR ARCHITECTURES OF BTB-CUL3 UBIQUITIN LIGASES: SPOPBTB/3-BOX
492, p3htmA2, 0.5043, 1.97, 0.227, 87, 75, STRUCTURES OF SPOP-SUBSTRATE COMPLEXES: INSIGHTS INTO MOLECULAR ARCHITECTURES OF BTB-CUL3 UBIQUITIN LIGASES: SPOPBTB/3-BOX
493, p3htmC2, 0.5028, 1.66, 0.194, 84, 72, STRUCTURES OF SPOP-SUBSTRATE COMPLEXES: INSIGHTS INTO MOLECULAR ARCHITECTURES OF BTB-CUL3 UBIQUITIN LIGASES: SPOPBTB/3-BOX
